Home › Funds › Catalys Pacific, LLC › PHAT
Catalys Pacific, LLC position in PHAT
Phathom Pharmaceuticals, Inc. · Health Care
Catalys Pacific, LLC reported holding 1,882,039 shares of PHAT (Phathom Pharmaceuticals, Inc.) in its Q3 2026 13F filing — a position valued at US$13.7M, representing 6.55% of its reported portfolio and ranking #2 among its reported holdings. Catalys Pacific, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-10-30 · Source: SEC EDGAR Form 13F-HR
How Catalys Pacific, LLC's PHAT position evolved
Catalys Pacific, LLC first disclosed a stake in PHAT in Q4 2023 at 721,962 shares (US$6.6M). The position peaked in Q4 2025 at 1,429,014 shares, worth US$23.7M. Across 12 filings, Catalys Pacific, LLC increased the stake 5 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 1,882,039 shares valued at US$13.7M — an increase of 388,185 shares quarter over quarter.. Notable position changes include a 55% increase in Q3 2024 (shares fell 55% over the following quarter), a 26% increase in Q3 2026 (shares fell 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 721.96K | $6.59M | New |
| Q1 2024 | 721.96K | $7.67M | Hold |
| Q2 2024 | 721.96K | $7.44M | Hold |
| Q3 2024 | 1.12M | $20.30M | Add |
| Q4 2024 | 1.17M | $9.48M | Add |
| Q1 2025 | 1.17M | $7.32M | Hold |
| Q2 2025 | 1.17M | $11.19M | Hold |
| Q3 2025 | 1.17M | $13.74M | Hold |
| Q4 2025 | 1.43M | $23.71M | Add |
| Q1 2026 | 1.49M | $16.60M | Add |
| Q2 2026 | 1.49M | $16.21M | Hold |
| Q3 2026 | 1.88M | $13.74M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHAT and 13F data
PHAT (Phathom Pharmaceuticals, Inc.) is a Health Care company. 30 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Frazier Life Sciences Management, L.P. 12.47M sh · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M sh · $80.99M · Q2 2026
- Carlyle Group Inc. 3.50M sh · $37.94M · Q2 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M sh · $20.07M · Q2 2026
- Propel Bio Management, LLC 1.05M sh · $11.40M · Q2 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on Catalys Pacific, LLC
FAQ
How long has Catalys Pacific, LLC held PHAT?
Catalys Pacific, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Catalys Pacific, LLC's current position in PHAT?
As of Q3 2026, Catalys Pacific, LLC holds 1.88M shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $13.74M, representing 6.55% of its reported portfolio and ranking #2.
Has Catalys Pacific, LLC been buying or selling PHAT?
In the latest 13F filing (Q3 2026), Catalys Pacific, LLC increased its position in PHAT. The position peaked in Q4 2025 at 1.43M shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.